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Fortunately, the introduction of assisted reproduction 
techniques (ARTs), in particular the intrauterine insemi-
nation (IUI) and the in vitro fertilization (IVF), have wid-
en the spectrum of the therapeutic options for infertile 
couples.
Human follicle-stimulating hormone (hFSH) has been 
introduced in order to increase sperm concentration, sper-
matogonial population, or both natural or assisted pregnancy 
rates in oligozoospermic subjects with normal plasma con-
centrations of gonadotropins (2).
On the basis of these considerations, some uncontrolled 
studies have shown an improvement of seminal parameters 
and/or an increase of pregnancy rates in infertile men with 
normogonadotropic oligozoospermia or azoospermia treated 
with different doses of FSH (3).
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Introduction
Recent evidences have clearly demonstrated that male fac-
tor alone is responsible for nearly 30% cases of infertility (1).
ABSTRACT
Introduction: Recent evidences demonstrated that male factor alone is responsible for about 30% cases of in-
fertility. Human follicle-stimulating hormone (hFSH) has been introduced to increase sperm concentration, sper-
matogonial population, or both natural or assisted pregnancy rates (PRs) in oligozoospermic subjects with normal 
concentrations of gonadotropins.
Methods: Fifty infertile men affected by idiopathic azoospermia were enrolled in this study, after undergoing 
medical history, physical and clinical examination, baseline semen parameters and hormonal plasma concentra-
tions. Inclusion criteria were infertility for at least 2 years, idiopathic azoospermia, FSH <12 mIU/ml. Twenty-five 
patients were allocated to treatment with hFSH three times/week per 3 months (Fostimon), and 25 patients 
underwent just testicular sperm extraction (TESE) without medical treatment. All patients underwent, after 
3 months, assisted reproduction techniques (ARTs) with TESE. The primary outcome was represented by the dif-
ferences in the sperm retrieval rate (SRR) between groups, while the secondary outcomes were the differences 
in PR and fertilization rate (FR).
Results: We observed a PR of 15% (3/25) and 28% (7/25) in control and treated group, respectively. SRR after 
medical treatment and ART was 24% (6/25), while in the control group was 12.5% (2/25). The sperm in the ejacu-
late of five patients (20%) after medical treatment exhibited a mean concentration of 0.9 million/ml and a mean 
motility of 12%. The FR was significantly greater in the treatment group with respect to the control group, 30% 
and 20%, respectively.
Conclusions: FSH treatment showed greater efficacy rather than control by increasing the rate of PR and FR in 
azoospermic patients who underwent TESE.
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Moreover, in order to minimize testicular damage during 
testicular sperm extraction (TESE), some researchers have 
sought to evaluate the role of hormone therapy for restoring 
spermatogenesis in men with particular idiopathic azoosper-
mia (4).  In fact, although the treated patients may remain 
azoospermic, the therapy may increase the retrieval rates of 
TESE.
However, considering the weakness of scientific evidenc-
es in this field of the reproductive medicine, we structured a 
prospective study aiming to evaluate the safety and efficacy 
of treatment with highly purified human-derived follicle-
stimulating hormone (HP Urofollitropin) in patients with idio-
pathic azoospermia before TESE.
Methods
A total of 50 men referred to our referral center for couple 
infertility and affected by idiopathic azoospermia were enrolled 
in this prospective study. All patients underwent detailed med-
ical anamnesis and clinical examination before recruitment. 
The baseline semen parameters and hormonal levels (FSH, 
luteinizing hormone, total testosterone and inhibin B) were 
collected for each patient. Inclusion criteria were as following: 
couple infertility for at least 2 years, idiopathic azoospermia, 
understood as a form of azoospermia with unknown etiology, 
FSH <12 mIU/ml, and testicular volume between 12 and 20 ml. 
Exclusion criteria were drug hypersensivity, abnormal bleed-
ing, adrenal dysfunction, intracranial lesion, and uncontrolled 
thyroid.
The results of two separate semen analyses confirmed 
the diagnosis of azoospermia (i.e., no spermatozoa after ex-
amination of the centrifuged pellet). The two sperm samples 
were analyzed according to the World Health Organization 
2010 guidelines.
One group of 25 patients was allocated to the treatment 
with hFSH, injected subcutaneously three times/week per 
3 months (Fostimon 150 IU/injection) diluted with physiologi-
cal saline, while another group of 25 patients, retrospectively 
analyzed, was treated just with TESE without a previous med-
ical treatment.
Finally, all patients underwent a TESE procedure in an at-
tempt to retrieve testicular sperm suitable for intracytoplas-
matic sperm injection (ICSI).
Sperm was researched by placing in a petri dish filled with 
0.5 ml of human tubal fluid medium, minced and shredded 
using sterile glass slides. Then, each sample was examined 
immediately by placing a small droplet.
The primary outcome was represented by the differences 
in the sperm retrieval rate between groups, while the second-
ary outcomes were the differences in terms of pregnancy rate 
and fertilization rate, respectively. Drug safety was evaluated 
by pre- and post-treatment blood biochemistry and hematol-
ogy, and recording all side effects.
Continuous variables are presented as mean ± standard 
deviation (SD) and differences between groups were tested 
by Student’s independent t-test or Mann-Whitney U-test ac-
cording to their distribution, respectively (normality of vari-
ables’ distribution was tested by Kolmogorov-Smirnov test). 
Categorical variables were tested with the Chi-square analy-
sis. All tests were completed using SPSS v. 19 software (SPSS 
Inc, IBM Corp, Somers, New York, USA). For all statistical com-
parisons, significance was considered as p<0.05.
Results
Table I lists the characteristics of patients at the enroll-
ment. As clearly shown, groups were well balanced at the 
baseline. As summarized in Table II, the sperm in the ejacu-
late of five patients (20%) after medical treatment exhibited 
a mean (SD) concentration of 0.9 (0.7) million/ml and a mean 
(SD) motility of 12% (10%). We noted that the sperm retrieval 
rate after medical treatment and TESE was 24% (6/25), while 
in the control group was 12.5% (2/25). The fertilization rate 
was significantly greater in the treatment group with respect 
to the control group, 30% and 20%, respectively (p<0.05). 
At the final follow-up, we observed a pregnancy rate of 15% 
(3/25) and 28% (7/25) in control and treated group, respec-
tively (p<0.05).
Finally, we did not find any statistically differences in age, 
testicular volume, initial serum total testosterone, or FSH in 
patients with successful sperm retrieval as compared with 
those without sperm found at TESE.
Conclusion
The aim of the present pilot study is to evaluate the ef-
fects of hFSH administration before TESE in men affected by 
infertility secondary to idiopathic azoospermia.
It has been previously published by Schill et al, who noted 
an increase in mean sperm concentration of 15.3 million/ml 
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TABLE I - Baseline characteristics of included patients
Control Treated
Number of subjects 25 25
Age of patients, years (mean ± SD) 34.0 ± 4.0 35.5 ± 4.3
Infertility duration, years (mean ± SD) 3.2 ± 2.2 3.4 ± 2.5
Body mass index, kg/m2 (mean ± SD) 22.3 ± 1.8 22.5 ± 2.0
Ejaculate volume, ml (mean ± SD) 3.2 ± 2.4 3.1 ± 2.0
Testosterone, nmol/l (mean ± SD) 12.0 ± 2.4 12.8 ± 3.5
LH, mIU/ml (mean ± SD) 5.3 ± 2.8 5.5 ± 2.5
FSH, mIU/ml (mean ± SD) 7.7 ± 2.2 7.8 ± 2.4
TABLE II - Primary and secondary outcomes after treatment
Control Treated p
Sperm in semen, % 0 (0) 5 (20) <0.05
Pregnancy rate, n (%) 3 (15) 7 (28) <0.05
Sperm retrieval rate, n (%) 7 (28) 10 (40) <0.05
Fertilization rate, n (%) 5 (20) 8 (30) <0.05
Cocci et al  3
© 2017 Wichtig Publishing  
after 3 months of treatment with human chorionic gonado-
tropin (hCG) and human menopausal gonadotropin (hMG) 
in men with idiopathic oligospermia and normal levels of 
gonadotropin (5).
In the past decade, andrologists had clomiphene citrate, 
hCG and hMG as treatment for idiopathic oligospermia, re-
porting improvement in semen quality and increased preg-
nancy rates among the partners of men in whom these agents 
were administered (6, 7).
A systematic review and meta-analysis showed a sig-
nificant 4% increase in live-birth rate with the use of hMG, 
when compared with recombinant FSH (rFSH), following a 
long downregulation protocol in IVF-ICSI treatment cycles 
(8). Hussein et al showed that for the patients who did not 
respond to clomiphene citrate as sole therapy and were 
managed with addition of hCG with or without hMG, 60% 
of patients ultimately had sperm available for ICSI. Authors 
observed that these patients had an approximately doubled 
sperm retrieval rate compared with the control group, and 
the increased availability of sperm from each group of medi-
cally treated patients compared with the control group was 
significant (p<0.05).
Herein, we demonstrate that patients treated with hFSH 
showed greater benefits than the control group in terms of 
pregnancy rate and sperm retrieval rate.
The physiologic regulation of spermatogenesis is still not 
completely understood. In particular, FSH is one of the major 
hormones produced by the anterior pituitary gland, activates 
the proliferation of the sertoli cells, and then induces the 
mitotic activity of the spermatogonia and supports cellular 
differentiation until the round spermatid stage (7). Recently, 
the use of hFSH or rFSH has been addressed with the aim to 
investigate the putative role of this hormone for the treat-
ment of infertility. It is possible that germ cells increase in 
seminiferous tubule causing testicular volume to increase (8).
Ding et al studied a total of 354 men affected by idiopathic 
oligozoospermia from three medical centers: sperm number 
was significantly increased after treatment with FSH at doses 
of at least 200 IU, and the improvement was observed begin-
ning at the third month. Moreover, 300 IU recombinant hu-
man FSH (rhFSH) administration for 5 months improved the 
spontaneous pregnancy rate and ART pregnancy rate.
The clinical efficacy of FSH treatment could be second-
ary to the promotion of spermatogenesis in seminiferous 
tubules. The possible mechanisms that FSH maintains sper-
matogenesis may be (i) activating the proliferation of the ser-
toli cells; (ii) increasing the number of type A spermatogonia; 
(iii) inducing the mitotic activity of the spermatogonia and 
supporting cellular differentiation until the round spermatid 
stage (9, 10).
Some studies have suggested that rhFSH treatment could 
restore sperm structure and increased sperm DNA condensa-
tion in idiopathic infertile men (9).
However, our study has several limitations. First of all, the 
lack of placebo and the absence of an additional subanalysis 
(i.e., age adjusted, comorbidities adjusted) should be under-
lined. Moreover, there are no different types of FSH treat-
ment, nor several doses and the short follow-up could have 
limited the evaluation of the pregnancy rate.
In conclusion, FSH treatment could be used to increase 
ART efficacy in infertile men with idiopathic azoospermia, but 
further studies, larger and placebo-controlled, are needed to 
confirm our preliminary data.
We demonstrated that FSH treatment showed greater 
efficacy rather than control by increasing the rate of preg-
nancy rate and fertilization rate in azoospermic patients 
who underwent TESE.
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